Daniel Bradbury

Daniel Bradbury has had a long and varied career in the life sciences industry. In 2012, they became the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm. In 2014, they took on the role of Executive Chairman at Sensulin. In 2016, they were appointed Director of Intercept Pharmaceuticals. In 2017, they became Executive Chairman and Chairman of the Board and Chief Executive Officer at Equillium, Inc. and Chairman of the Board at Biolinq, respectively. In 2018, they were appointed Director of DelNova. In 2019, they were appointed Director of Synedgen, Inc. and IQHQ REIT. In 2020, they were appointed Director of Alume Biosciences. Finally, in 2021, they became Executive Chairman of Amplo Biotechnology, Inc.

Daniel Bradbury began their educational journey at Dr.Challoner's Grammar School from 1972 to 1979. Daniel then attended the University of Nottingham from 1980 to 1983, graduating with a Bachelor of Pharmacy (B.Pharm.). During this time, they also studied at Harding High School in St. Paul, Minnesota from 1975 to 1976, and Battle Creek Junior High in St. Paul, Minnesota from 1974 to 1975. In 1994, they completed an Advanced Management Program (AMP) at INSEAD.